Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) - Join Clinical Trial NCTNCT06960577
How to Join This Clinical Trial - NCTNCT06960577
Learn how to participate in this PHASE3 trial studying an investigational therapy for Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE3 - Large-scale efficacy study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT06960577 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 52 locations. Find a study site near you:
Clinical Research Site
Chermside, 4032 - Australia
Status: RECRUITING
Clinical Research Site
Elizabeth Vale, 5112 - Australia
Status: NOT_YET_RECRUITING
Clinical Research Site
Heidelberg, 3084 - Australia
Status: NOT_YET_RECRUITING
Clinical Research Site
Hong Kong, - Australia
Status: NOT_YET_RECRUITING
Clinical Research Site
Kogarah, 2217 - Australia
Status: NOT_YET_RECRUITING
Clinical Research Site
Macquarie University, 2109 - Australia
Status: RECRUITING
Clinical Research Site
Murdoch, 6150 - Australia
Status: NOT_YET_RECRUITING
Clinical Research Site
Port Macquarie, 2444 - Australia
Status: NOT_YET_RECRUITING
Clinical Research Site
St Leonards, 2065 - Australia
Status: RECRUITING
Clinical Research Site
Barretos, 14784-400 - Brazil
Status: NOT_YET_RECRUITING
And 42 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE3 clinical trial for Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships